Results of a Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Study of the Effi cacy and Safety of Mexidol in Prolonged Sequential Therapy of Patients in the Acute and Early Recovery Stages of Hemispheric Stroke (the EPICA study)
This article is in “Library” section.
Author:
L. V. Stakhovskaya1, N. A. Shamalov1, D. R. Khasanova2, E. V. Mel’nikova3, A. S. Agaf’ina4, K. V. Golikov5, E. I. Bogdanov6, A. A. Yakupova6, L. V. Roshkovskaya7, L. V. Lukinykh8, T. M. Lokshtanova9, I. E. Poverennova10, and L. A. Shchepankevich11
1 Research Institute of Cerebrovascular Pathology and Stroke, Pirogov Russian National Research Medical University, Russian Ministry of Health, Moscow, Russia; e-mail: lstakh@mail.ru.
2 Interregional Clinical Diagnostic Center, Kazan, Russia.
3 St. Petersburg City Clinical Hospital No. 26, St. Petersburg, Russia.
4 St. Petersburg City Clinical Hospital No. 40 of the Resort Administrative District, St. Petersburg, Russia.
5 St. Petersburg City General Hospital No. 2, St. Petersburg, Russia.
6 Kazan Sate Medical University, Russian Ministry of Health, Kazan, Russia.
7 Nikolaevskaya Hospital, St. Petersburg, Russia.
8 Vsevolzhsk Clinical Interregional Hospital, Leningradskaya Oblast, Russia.
9 Pirogov City Clinical Hospital No. 1, Samara, Russia.
10 Seredavin Samara Regional Clinical Hospital, Samara, Russia.
11 Research Institute of Experimental and Clinical Medicine, Novosibirsk, Russia.